Vigilare Wealth Management Has $416,000 Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)


Share on StockTwits

Vigilare Wealth Management trimmed its stake in Bristol-Myers Squibb (NYSE:BMY) by 29.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,709 shares of the biopharmaceutical company’s stock after selling 2,748 shares during the quarter. Vigilare Wealth Management’s holdings in Bristol-Myers Squibb were worth $416,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of BMY. United Bank raised its position in Bristol-Myers Squibb by 2.7% in the 2nd quarter. United Bank now owns 19,914 shares of the biopharmaceutical company’s stock worth $1,171,000 after purchasing an additional 526 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of Bristol-Myers Squibb by 52.6% during the second quarter. Jacobs Levy Equity Management Inc. now owns 10,879 shares of the biopharmaceutical company’s stock worth $640,000 after acquiring an additional 3,750 shares in the last quarter. Stephens Inc. AR increased its position in shares of Bristol-Myers Squibb by 6.3% during the second quarter. Stephens Inc. AR now owns 142,708 shares of the biopharmaceutical company’s stock worth $8,391,000 after acquiring an additional 8,460 shares in the last quarter. WFA of San Diego LLC bought a new stake in shares of Bristol-Myers Squibb during the second quarter worth about $631,000. Finally, Garde Capital Inc. bought a new stake in shares of Bristol-Myers Squibb during the second quarter worth about $211,000. Hedge funds and other institutional investors own 72.41% of the company’s stock.

In other news, SVP Adam Dubow sold 900 shares of the firm’s stock in a transaction on Tuesday, November 24th. The stock was sold at an average price of $63.39, for a total value of $57,051.00. Following the completion of the transaction, the senior vice president now owns 15,186 shares in the company, valued at $962,640.54. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Rupert Vessey sold 57,591 shares of the firm’s stock in a transaction on Thursday, November 19th. The shares were sold at an average price of $61.30, for a total value of $3,530,328.30. Following the completion of the transaction, the executive vice president now owns 46,142 shares of the company’s stock, valued at approximately $2,828,504.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 71,915 shares of company stock worth $4,410,814. Corporate insiders own 0.14% of the company’s stock.

Several equities research analysts have recently commented on the stock. Berenberg Bank assumed coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, September 29th. They set a “buy” rating and a $73.00 target price for the company. Smith Barney Citigroup boosted their target price on shares of Bristol-Myers Squibb from $73.00 to $77.00 in a research note on Monday, November 30th. Raymond James restated a “buy” rating on shares of Bristol-Myers Squibb in a research note on Friday, September 25th. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $72.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, November 10th. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell increased their price target on shares of Bristol-Myers Squibb from $73.00 to $77.00 in a report on Monday, November 30th. Five equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $73.75.

BMY traded up $1.29 during trading on Thursday, reaching $66.02. 363,577 shares of the company’s stock were exchanged, compared to its average volume of 12,710,041. Bristol-Myers Squibb has a 1 year low of $45.76 and a 1 year high of $68.34. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.67 and a quick ratio of 1.58. The stock has a market capitalization of $149.38 billion, a P/E ratio of -588.40, a price-to-earnings-growth ratio of 0.94 and a beta of 0.67. The company’s fifty day simple moving average is $62.09 and its 200-day simple moving average is $74.86.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Tuesday, November 10th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.14. The firm had revenue of $10.54 billion during the quarter, compared to analyst estimates of $10.33 billion. Bristol-Myers Squibb had a negative net margin of 0.11% and a positive return on equity of 27.48%. The business’s quarterly revenue was up 75.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.17 EPS. Equities analysts forecast that Bristol-Myers Squibb will post 6.35 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, February 1st. Stockholders of record on Monday, January 4th will be given a dividend of $0.49 per share. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.45. The ex-dividend date is Thursday, December 31st. This represents a $1.96 annualized dividend and a dividend yield of 2.97%. Bristol-Myers Squibb’s payout ratio is presently 41.79%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.

Featured Story: Forex

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.